Cover Image
市場調查報告書

PLx Pharma Inc. - 產品平台分析

PLx Pharma Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 219795
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
PLx Pharma Inc. - 產品平台分析 PLx Pharma Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 29 Pages
簡介

PLx Pharma Inc.是總公司設立於美國的製藥企業,正從事非類固醇系抗發炎劑的開發。對象領域是退化性關節炎,疼痛,發熱,預防心臟疾病等。該公司的PLxGuard科技是可降低NSAID對腸胃造成的副作用之技術。

本報告提供PLx Pharma Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

PLx Pharma Inc.的基本資料

  • PLx Pharma Inc.概要
  • 主要資訊
  • 企業資料

PLx Pharma Inc.:R&D概要

  • 主要的治療範圍

PLx Pharma Inc.:開發平台分析

  • 各開發階段的開發中產品
  • 單劑產品

PLx Pharma Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

PLx Pharma Inc.:藥物簡介

  • aspirin
  • Diclofenac-PC
  • Ketorolac-PC
  • PL-1100
  • PL-4100
  • PL-4500
  • PL-5100

PLx Pharma Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

PLx Pharma Inc.:最近的開發平台資訊

PLx Pharma Inc.:暫停開發中的計劃

PLx Pharma Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07096CDB

Summary

Global Markets Direct's, 'PLx Pharma Inc. - Product Pipeline Review - 2015', provides an overview of the PLx Pharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PLx Pharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of PLx Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of PLx Pharma Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the PLx Pharma Inc.'s pipeline products

Reasons to buy

  • Evaluate PLx Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of PLx Pharma Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the PLx Pharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of PLx Pharma Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of PLx Pharma Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of PLx Pharma Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • PLx Pharma Inc. Snapshot
    • PLx Pharma Inc. Overview
    • Key Information
    • Key Facts
  • PLx Pharma Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • PLx Pharma Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • PLx Pharma Inc. - Pipeline Products Glance
    • PLx Pharma Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • PLx Pharma Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • PLx Pharma Inc. - Drug Profiles
    • aspirin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Diclofenac-PC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ketorolac-PC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PL-1100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PL-4100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PL-4500
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PL-5100
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • PLx Pharma Inc. - Pipeline Analysis
    • PLx Pharma Inc. - Pipeline Products by Target
    • PLx Pharma Inc. - Pipeline Products by Route of Administration
    • PLx Pharma Inc. - Pipeline Products by Molecule Type
    • PLx Pharma Inc. - Pipeline Products by Mechanism of Action
  • PLx Pharma Inc. - Recent Pipeline Updates
  • PLx Pharma Inc. - Dormant Projects
  • PLx Pharma Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • PLx Pharma Inc., Key Information
  • PLx Pharma Inc., Key Facts
  • PLx Pharma Inc. - Pipeline by Indication, 2015
  • PLx Pharma Inc. - Pipeline by Stage of Development, 2015
  • PLx Pharma Inc. - Monotherapy Products in Pipeline, 2015
  • PLx Pharma Inc. - Phase III, 2015
  • PLx Pharma Inc. - Preclinical, 2015
  • PLx Pharma Inc. - Discovery, 2015
  • PLx Pharma Inc. - Pipeline by Target, 2015
  • PLx Pharma Inc. - Pipeline by Route of Administration, 2015
  • PLx Pharma Inc. - Pipeline by Molecule Type, 2015
  • PLx Pharma Inc. - Pipeline Products by Mechanism of Action, 2015
  • PLx Pharma Inc. - Recent Pipeline Updates, 2015
  • PLx Pharma Inc. - Dormant Developmental Projects,2015

List of Figures

  • PLx Pharma Inc. - Pipeline by Top 10 Indication, 2015
  • PLx Pharma Inc. - Pipeline by Stage of Development, 2015
  • PLx Pharma Inc. - Monotherapy Products in Pipeline, 2015
  • PLx Pharma Inc. - Pipeline by Top 10 Target, 2015
  • PLx Pharma Inc. - Pipeline by Top 10 Route of Administration, 2015
  • PLx Pharma Inc. - Pipeline by Top 10 Molecule Type, 2015
  • PLx Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top